Business Strategy, Partnerships, Presentation, and Appointment - Research Report on Merck, GSK, Sanofi, Intercept, and KYTHERA

  Business Strategy, Partnerships, Presentation, and Appointment - Research
             Report on Merck, GSK, Sanofi, Intercept, and KYTHERA

PR Newswire

NEW YORK, October 4, 2013

NEW YORK, October 4, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Merck &
Co. Inc. (NYSE: MRK), GlaxoSmithKline plc (NYSE: GSK), Sanofi (NYSE: SNY),
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), and KYTHERA
Biopharmaceuticals, Inc. (NASDAQ: KYTH). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Merck & Co. Inc. Research Report

On October 1, 2013, Merck & Co. Inc. (Merck) announced the intention to move
its global headquarters from Whitehouse Station, N.J., to its existing
facilities in Kenilworth, N.J. Merck reported that based on the evaluation of
its real estate needs in the state, it has determined that it could achieve
greater cost savings and operational synergies by closing both its Summit
campus and its main Whitehouse Station facility. The Company's Animal Health
and Consumer Care divisions currently located in Summit will be relocated to
another facility in New Jersey, while certain manufacturing, laboratory and
other functions currently located in Summit will be relocated to other
facilities in New Jersey or Pennsylvania. Merck expects to begin the
transition in 2014 and complete by 2015. The Company stated that these plans
are part of its global initiative to sharpen its commercial and R&D focus and
reduce costs, including the size of its workforce and global real estate
footprint. The Full Research Report on Merck & Co. Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/430d_MRK]

--

GlaxoSmithKline plc Research Report

On September 27, 2013, GlaxoSmithKline plc (GSK) announced its partnership
with Barclays to increase access to affordable healthcare and medicines for
people in Zambia, while helping to create improved economic conditions for
growth. GSK reported that the partnership aims to help remove financial
barriers to healthcare access, while supporting small business development and
job creation. Sir Andrew Witty, CEO of GSK, commented, "Though prospects for
growth are improving, Zambia still experiences significant healthcare
challenges. By combining our specific resources and skills with those of
Barclays, we can help unblock financial barriers and enhance government
efforts to help increase access to affordable healthcare. Good health is vital
for people to live more productive lives, which in turn will help to create
the right conditions for Zambia's economic development and lead to a more
prosperous society." The Full Research Report on GlaxoSmithKline plc -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/2a35_GSK]

--

Sanofi Research Report

On September 27, 2013, Sanofi announced that it has renewed its cooperation
protocol with Aviesan, the French National Alliance for Life Sciences and
Health, for a period of three years. According to Sanofi, the renewal of the
agreement aims to contribute to the development of new treatments that target
unmet medical needs, including those in the field of rare diseases, to
participate to the excellence and consolidation of research in French industry
on an international level. The Company reported that a special emphasis will
be put on translational research projects that bring together clinical and
medical teams with fundamental research teams to translate research successes
into medical advances. Sanofi reported that under the new protocol, the
research teams of both the Companies will spur the development of technology
platforms to finance the work of researchers, CIFRE fellows, post-docs, and
staff secondment. The Full Research Report on Sanofi - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.AnalystsCorner.com/r/full_research_report/29ea_SNY]

--

Intercept Pharmaceuticals, Inc. Research Report

On October 1, 2013, Intercept Pharmaceuticals, Inc. (Intercept) announced that
two analyses by the Global Primary Biliary Cirrhosis (PBC) Study Group (PBC
Supergroup) have been accepted for oral presentation at the 64th Annual
Meeting of the American Association for the Study of Liver Diseases (AASLD) on
November 1 to 5, 2013 in Washington, D.C. Intercept revealed that data from
over 3,895 PBC patients collected and pooled by an independent group of 15
academic medical centers across eight countries have been analyzed by the PBC
Supergroup. The Company stated that the analyses are expected to further
confirm that the surrogate biochemical endpoint used by Intercept in its
ongoing Phase 3 POISE trial (i.e., alkaline phosphatase (ALP) < 1.67x upper
limit of normal and normal bilirubin) is strongly predictive of adverse
clinical outcomes in PBC patients. Intercept further informed that the two
abstracts from the PBC Supergroup are available at the AASLD website. The Full
Research Report on Intercept Pharmaceuticals, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.AnalystsCorner.com/r/full_research_report/b477_ICPT]

--

KYTHERA Biopharmaceuticals, Inc. Research Report

On September 19, 2013, KYTHERA Biopharmaceuticals, Inc. (KYTHERA) announced
the appointment of Hospira's CEO F. Michael (Mike) Ball to its Board of
Directors. Keith Leonard, President and CEO of KYTHERA, commented, "Mike's
breadth of experience in developing the global aesthetic market and leading
product brands such as BOTOX Cosmetic®, JUVEDERM® and Latisse® make him an
ideal addition to the KYTHERA Board." Leonard added, "We are thrilled to have
him on board. His knowledge and perspective will support our mission to bring
innovation to the growing area of aesthetic medicine." The Full Research
Report on KYTHERA Biopharmaceuticals, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.AnalystsCorner.com/r/full_research_report/b90a_KYTH]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America)